A Phase 2, multi-center, randomized, double blind, placebo controlled study in subjects with late prodromal and early manifest Huntington Disease )HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Vaccinex, Inc.
Start Date
July 1, 2015
End Date
December 31, 2021
Administered By
Neurology, Movement Disorders
Awarded By
Vaccinex, Inc.
Start Date
July 1, 2015
End Date
December 31, 2021